Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
IPO Year: 2014
Exchange: NASDAQ
Website: https://www.societalcdmo.com
15-12G - Societal CDMO, Inc. (0001588972) (Filer)
EFFECT - Societal CDMO, Inc. (0001588972) (Filer)
EFFECT - Societal CDMO, Inc. (0001588972) (Filer)
EFFECT - Societal CDMO, Inc. (0001588972) (Filer)
POS AM - Societal CDMO, Inc. (0001588972) (Filer)
POS AM - Societal CDMO, Inc. (0001588972) (Filer)
POS AM - Societal CDMO, Inc. (0001588972) (Filer)
S-8 POS - Societal CDMO, Inc. (0001588972) (Filer)
S-8 POS - Societal CDMO, Inc. (0001588972) (Filer)
S-8 POS - Societal CDMO, Inc. (0001588972) (Filer)
SAN DIEGO and GAINESVILLE, Ga., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO"; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the appointment of Matt Arens to the company's board of directors. Mr. Arens has more than 25 years of experience as a successful investment professional identifying innovative life science companies with high growth potential. For the past 15 years, he solely has managed dedicated health care portfolios. Mr. Arens currently serves as chief executive officer and senior po
SAN DIEGO and GAINESVILLE, Ga., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO"; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the appointment of Elena Cant to the company's board of directors. Ms. Cant has more than 20 years of diverse business experience ranging across various functions including corporate development, business operations and strategy, marketing, commercial, manufacturing, and research and development. She has an impressive track record of establishing and growing functional groups,
SC 13D/A - Societal CDMO, Inc. (0001588972) (Subject)
SC 13G - Societal CDMO, Inc. (0001588972) (Subject)
SC 13D - Societal CDMO, Inc. (0001588972) (Subject)
4 - Societal CDMO, Inc. (0001588972) (Issuer)
4 - Societal CDMO, Inc. (0001588972) (Issuer)
4 - Societal CDMO, Inc. (0001588972) (Issuer)
4 - Societal CDMO, Inc. (0001588972) (Issuer)
4 - Societal CDMO, Inc. (0001588972) (Issuer)
4 - Societal CDMO, Inc. (0001588972) (Issuer)
4 - Societal CDMO, Inc. (0001588972) (Issuer)
4 - Societal CDMO, Inc. (0001588972) (Issuer)
4 - Societal CDMO, Inc. (0001588972) (Issuer)
4 - Societal CDMO, Inc. (0001588972) (Issuer)
CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the MergerCoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 20
CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the Merger CoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per Share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 2024 and was not further extended. The depositary an
Phase 3 Trial Initiation for Lead ADHD Candidate CTx-1301 in December 2022 Executed Manufacturing Agreement with Societal CDMO 2022 Psych Congress Presentation Demonstrated Ability of Anxiety Candidate CTx-2103 to Deliver a Single Administration of Triple-Release Buspirone KANSAS CITY, Kan., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended September 30, 2022 and provided a clinical and business update. Highlights include
Recorded Q1 Revenue of $21 Million; A 26% Increase Compared to Prior Year Period Signed Multiple New Business Agreements Spanning Early Stage Through Commercial Manufacturing Launching Aseptic Fill-Finish and Lyophilization Service in Q2 2022; Facilities Upgrades Continue Company to Host Conference Call Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., May 11, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO" or "Societal"; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the first quarte
SAN DIEGO and GAINESVILLE, Ga., May 04, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO" or "Societal"; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the first quarter 2022 after the market close on Wednesday, May 11, 2022. Societal's management team will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, May 11, 2022, to discuss the financial results and recent operational highlights. To access the live conference call please dial (844) 243
CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the MergerCoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 20
CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the Merger CoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per Share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 2024 and was not further extended. The depositary an
Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATER, Fla. and GAINESVILLE, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has entered into a definitive agreement with CoreRx, Inc. ("CoreRx") under which CoreR
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing through Process Development and cGMP Manufacturing to Fill/Finish GAINESVILLE, Ga. and ROUND ROCK, Texas, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (("Societal CDMO", NASDAQ:SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, and Benuvia Operations, LLC, a U.S.-based drug developer and manufacturer of active pharmaceutical ingredients (APIs) wit
SAN DIEGO and GAINESVILLE, Ga., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (("Societal CDMO", NASDAQ:SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the addition of new employees to fill open roles throughout the organization. Inducement Equity Award In connection with the hiring of these personnel, the compensation committee of Societal CDMO's board of directors approved inducement stock option grants to purchase an aggregate of 32,630 shares of Societal CDMO's common stock. The option awards were granted pursuant to th
Recorded Q3 Revenue of $23.6 Million Signed Multiple New Business Agreements with New and Existing Customers Closed Public Offering Raising Gross Proceeds of Approximately $8.3 Million Initiated Corporate Restructuring; Expected to Result in Annualized Savings of Approximately $5.5 Million Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (("Societal", NASDAQ:SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the third quarter and
SAN DIEGO and GAINESVILLE, Ga., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO" or "Societal"; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the third quarter 2023 after the market close on Wednesday, November 8, 2023. Societal's management team will host a webcast at 4:30 p.m. ET on that day to discuss the financial results and recent operational highlights. A live webcast can be accessed by visiting the "Investor Events" page in the Investor section
SAN DIEGO and GAINESVILLE, Ga., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (("Societal CDMO", NASDAQ:SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the addition of new employees to fill open roles throughout the organization. Inducement Equity Award In connection with the hiring of these personnel, the compensation committee of Societal CDMO's board of directors approved inducement stock option grants to purchase an aggregate of 43,230 shares of Societal CDMO's common stock. The option awards were granted pursuant to th
SAN DIEGO and GAINESVILLE, Ga., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (("Societal CDMO" or "Societal", NASDAQ:SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will participate at the RBC Capital Markets Virtual CDMO Conference. David Enloe, chief executive officer, will be the featured speaker in a fireside chat at the conference, which will take place October 2-3, 2023. Details of the company's participation are as follows: RBC Capital Markets Virtual CDMO ConferenceConference Date: October 2-3, 20
SAN DIEGO and GAINESVILLE, Ga., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (("Societal CDMO", NASDAQ:SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced a strategic restructuring plan to streamline and optimize operations. Following the completion of a comprehensive review of its operations, Societal has reduced its workforce by 26 positions (9%) across all aspects of the business, effective September 20, 2023. It also has eliminated nine open positions. These moves are expected to result in annualized savings of approxima
U.S. stocks traded mixed toward the end of trading, with the S&P 500 gaining around 0.3% on Thursday. The Dow traded down 0.08% to 38,919.26 while the NASDAQ rose 0.53% to 16,032.35. The S&P 500 also rose, gaining, 0.30% to 5,084.84. Check This Out: Robinhood, Shake Shack And 2 Other Stocks Insiders Are Selling Leading and Lagging Sectors Real estate shares rose by 1.2% on Thursday. In trading on Thursday, health care shares fell by 0.6%. Top Headline Shares of Hayward Holdings, Inc. (NYSE:HAYW) surged over 17% on Thursday after the company reported better-than-expected fourth-quarter results. Hayward Holdings posted adjusted earnings of 20 cents per share, beating mar
Shares of Butterfly Network, Inc. (NASDAQ:BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. Butterfly Network posted GAAP loss of 21 cents per share versus market estimates for a loss of 14 cents per share. The company’s quarterly sales came in at sales came in $16.52 million versus estimates of $15.35 million. Butterfly Network shares dipped 21.7% to $1.1588 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Enveric Biosciences, Inc. (NASDAQ:ENVB) gained 177.1% to $2.30 after the company announced it has signed three non-binding term sheets with an undisclosed biotechnology company to purs
Gainers Societal CDMO (NASDAQ:SCTL) stock rose 132.6% to $1.07 during Thursday's regular session. The company's market cap stands at $112.1 million. Enveric Biosciences (NASDAQ:ENVB) shares increased by 132.25% to $1.93. The market value of their outstanding shares is at $5.2 million. Envoy Medical (NASDAQ:COCH) stock rose 47.29% to $5.17. The market value of their outstanding shares is at $101.0 million. Tivic Health Systems (NASDAQ:TIVC) shares moved upwards by 30.39% to $1.63. The market value of their outstanding shares is at $2.3 million. Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 29.68% to $7.34. The company's market cap stands at $644.5 million. The company's, Q4 e
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded down 0.16% to 38,884.96 while the NASDAQ rose 0.38% to 16,008.19. The S&P 500 also rose, gaining, 0.16% to 5,077.83. Check This Out: Robinhood, Shake Shack And 2 Other Stocks Insiders Are Selling Leading and Lagging Sectors Real estate shares rose by 0.6% on Thursday. In trading on Thursday, health care shares fell by 0.5%. Top Headline Best Buy Co., Inc. (NYSE:BBY) posted better-than-expected fourth-quarter earnings. The company reported fourth-quarter adjusted earnings per share of $2.72, beating the street view of $2.51. Quarterly sales of
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded down 0.07% to 38,923.11 while the NASDAQ rose 0.65% to 16,051.57. The S&P 500 also rose, gaining, 0.30% to 5,084.74. Check This Out: Robinhood, Shake Shack And 2 Other Stocks Insiders Are Selling Leading and Lagging Sectors Communication services shares rose by 0.9% on Thursday. In trading on Thursday, health care shares fell by 0.6%. Top Headline The annual PCE inflation rate eased slightly from 2.6% in December 2023 to 2.4% in January 2024. Excluding energy and food, the core PCE index saw a year-on-year su
Privately held CoreRx Inc. will acquire Societal CDMO Inc (NASDAQ:SCTL), a contract development and manufacturing organization. CoreRx on Wednesday said it will commence a tender offer to acquire all outstanding shares of Societal CDMO for $1.10 per share in cash. “We are pleased to enter into this transaction with CoreRx, which delivers substantial value to our shareholders and is the outcome of a thorough review process overseen by the Societal CDMO board of directors,” said Wayne Weisman, executive chairman of Societal CDMO’s board of directors. The transaction is expected to close early in the second quarter of 2024. CoreRx is a CDMO providing drug formulation, development,
Gainers Enveric Biosciences (NASDAQ:ENVB) stock rose 162.3% to $2.18 during Thursday's pre-market session. The company's market cap stands at $5.9 million. Societal CDMO (NASDAQ:SCTL) shares moved upwards by 134.78% to $1.08. The company's market cap stands at $113.1 million. NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 45.11% to $7.43. The company's market cap stands at $36.4 million. OneMedNet (NASDAQ:ONMD) stock moved upwards by 28.97% to $0.89. The market value of their outstanding shares is at $28.7 million. Establishment Labs Hldgs (NASDAQ:ESTA) stock increased by 21.91% to $46.89. The market value of their outstanding shares is at $1.2 billion. As per the press relea
Shares of Okta, Inc. (NASDAQ:OKTA) shares rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued strong guidance. Okta reported quarterly earnings of 63 cents per share which beat the analyst consensus estimate of 51 cents. Quarterly sales came in at $605 million which beat the analyst consensus estimate of $587.5 million, according to data from Benzinga Pro. Okta shares jumped 23.6% to $107.90 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Volcon, Inc. (NASDAQ:VLCN) gained 138% to $2.88 in pre-market trading after surging around 39% on Wednesday. Societal CDMO, In
RBC Capital analyst Sean Dodge downgrades Societal CDMO (NASDAQ:SCTL) from Outperform to Sector Perform and lowers the price target from $1.25 to $1.1.